PT - JOURNAL ARTICLE AU - Polinski, Jennifer M. AU - Weckstein, Andrew R. AU - Batech, Michael AU - Kabelac, Carly AU - Kamath, Tripthi AU - Harvey, Raymond AU - Jain, Sid AU - Rassen, Jeremy A. AU - Khan, Najat AU - Schneeweiss, Sebastian TI - Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine AID - 10.1101/2021.09.10.21263385 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.10.21263385 4099 - http://medrxiv.org/content/early/2021/09/16/2021.09.10.21263385.short 4100 - http://medrxiv.org/content/early/2021/09/16/2021.09.10.21263385.full AB - Importance Vaccination against the SARS-CoV-2 virus is critical to control the pandemic. Randomized trials demonstrated efficacy of the single-dose Ad26.COV2.S COVID vaccine but data on longer-term protection in clinical practice and effectiveness against variants are needed.Objective To assess the effectiveness of Ad26.COV2.S in preventing COVID infections and COVID-related hospitalizations in clinical practice, the longer-term stability of its protective effect and effectiveness against Delta variants.Design Cohort study of newly Ad26.COV2.S-vaccinated and unvaccinated individuals.Setting U.S. insurance claims data through July 2021.Participants Individuals 18 years and older newly vaccinated with Ad26.COV2.S and up to 10 unvaccinated individuals matched exactly by age, sex, date, location, comorbidity index plus 17 COVID-19 risk factors via propensity score (PS) matching.Intervention Vaccination with Ad26.COV2.S versus no vaccination.Main outcomes We estimated vaccine effectiveness (VE) for observed COVID-19 infection and COVID-19-related hospitalization, nationwide and stratified by age, immunocompromised status, calendar time, and states with high incidence of the Delta variant. We corrected VE estimates for under-recording of vaccinations in insurance data.Results Among 390,517 vaccinated and 1,524,153 matched unvaccinated individuals, VE was 79% (95% CI, 77% to 80%) for COVID-19 and 81% (79% to 84%) for COVID-19-related hospitalizations. VE was stable over calendar time. Among states with high Delta variant incidence, VE during June/July 2021 was 78% (73% to 82%) for infections and 85% (73% to 91%) for hospitalizations. VE for COVID-19 was higher in individuals <50 years (83%; 81% to 85%) and lower in immunocompromised patients (64%; 57% to 70%). All estimates were corrected for under-recording; uncorrected VE was 69% (67% to 71%) and 73% (69% to 76%), for COVID-19 and COVID-19-related hospitalization, respectively.Conclusions These non-randomized data across U.S. clinical practices show high and stable vaccine effectiveness of Ad26.COV2.S over time before the Delta variant emerged to when the Delta variant was dominant.Competing Interest StatementDr. Polinski, Mr. Weckstein, Dr. Batech, Ms. Kabelac and Dr. Rassen are employees of and own stock options or equity in Aetion, a software-enabled healthcare analytics company. Dr. Kamath, Mr. Harvey, Mr. Jain and Dr. Khan are employees of Janssen R&D, the manufacturer of the studied vaccine Ad26.COV2.S. Dr. Schneeweiss (ORCID# 0000-0003-2575-467X) is participating in investigator-initiated grants to the Brigham and Women's Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc. of which he owns equity. His interests were declared, reviewed, and approved by the Brigham and Women's Hospital in accordance with their institutional compliance policies.Funding StatementThis work was funded by Janssen R&DAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the New England institutional review board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData belong to third parties and cannot be shared publicly, however, upon reasonable request, researchers may get access to the data and analytics infrastructure for pre-specified collaborative analyses.